适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- AMED
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 50years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Treatment with another anti-amyloid investigational drug or other intervention within 12 months (exception allowed) 2. Enrolled in another interventional clinical trial within the last 12 weeks
研究者
相似试验
已完成
不适用
Japanese multicenter REsearch of COVID-19 by assEmbling Real-world dataCOVID-19JPRN-UMIN000047056ippon Medical School Musashikosugi Hospital4,700
招募中
不适用
A high evidence-based RCT study of Huatan Qushi Huoxue granule on intervention of obese non-alcoholic steatosis patientsnon-alcoholic steatohepatitisITMCTR2200006122The First Affiliated Hospital of Henan University of CM
已完成
不适用
Pivotal study about efficiency and safety of JTEC-01 made from revertant mosaicism in epidermolysis bullosarecessive dystrophic epidermolysis bullosa or junctional epidermolysis bullosaJPRN-UMIN000020734Hokkaido University Hospital3
进行中（未招募）
1 期
Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast Cancerung Cancer or Breast CancerCTIS2023-506788-32-00Eli Lilly & Co.1
招募中
不适用
J-REGISTER: Japanese REal-world data for treatment of afatinib (GIotrif) in first-line setting and Subsequent Therapies for patients with advanced EGFR mutation-positive lung adenocarcinomaJPRN-UMIN000044071ippon Boehringer Ingelheim Co., Ltd.1,000